Acexamic acid (N-acetyl-amino-6-hexanoic acid) is a drug used as a cicatrization helper. Some studies show that the acexamic acid prevents the formation the connective inflamed tissue and enables its healing. The association from acexamic acid with zinc, zinc acexamate, has been used in the treatment of gastric and duodenal ulcer and in the prevention of gastric ulcer induced by nonsteroidal anti-inflammatory drugs.

Fenclozic acid emerged in the late 1960s as a promising carboxylic acid non-steroidal anti-inflammatory drug candidate that demonstrated potent anti-inflammatory, anti-pyretic and analgesic properties. Whole body autoradiography showed fenclozic acid distribution into all tissues except the brain, with radioactivity still detectable in blood, kidney and liver at 72 h post-dose. Fenclozic acid was compared with aspirin in a double-blind, crossover trial in patients with rheumatoid arthritis. It was concluded that fenclozic acid afforded symptomatic relief and was comparable to aspirin. Unfortunately, hepatotoxicity was observed in subsequent trials and the drug was withdrawn from the clinic.

Cicloxilic acid is a choleretic agent. Cicloxilic acid feeding lowered bile saturation (though bile tended to remain more saturated than normal) without affecting total bile acid pool size. The efficacy of cicloxilic acid in lowering biliary cholesterol saturation was not due to changes of dietary cholesterol absorption or of hepatic cholesterol synthesis. Hepatic cholesterogenesis and dietary cholesterol absorption are unaffected by cicloxilic acid feeding. Since cicloxilic acid is safe, cheap and lowers bile cholesterol saturation, this compound might have a place in gallstone disease either in association with the litholytic bile acids or in prevention of stone formation in high-risk populations (diabetics, obese, hyperlipidemic, etc.).

Butedronic acid is used for diagnostic purposes. Tetrasodium salt of butedronic acid is bone imaging agent.

Magnesium isoglycyrrhizinate is a magnesium salt form of isoglycyrrhizinate, a derivative of glycyrrhizic acid extracted from the roots of the plant Glycyrrhiza glabra. Magnesium isoglycyrrhizinate has anti-inflammatory, antioxidant and hepatoprotective activities. The drug is believed to be a free radical scavenger and to modulate the activity of hepatic enzymes. Magnesium isoglycyrrhizinate was investigated in clinical trials to restore hepatic impairments caused by chemotherapy drugs and as a treatment of chronic liver diseases.

Minodronic acid (RECALBON®, Bonoteo®), a third-generation bisphosphonate, was approved in Japan for the oral treatment of osteoporosis. This drug increases the bone mineral density and the strength by inhibiting osteoclastic bone resorption. Nitrogen-containing bisphosphonates, such as minodronic acid (RECALBON®, Bonoteo®) induce osteoclast apoptosis by inhibiting farnesyl pyrophosphate synthase (FPPS), a key enzyme in the mevalonate pathway. Inhibition of FPPS in osteoclasts prevents the biosynthesis of isoprenoid lipids that are required for the prenylation of small GTPase signaling proteins necessary for osteoclast function. Similarly, nitrogen-containing bisphosphonates have been shown to inhibit farnesyl pyrophosphate/geranyl pyrophosphate synthase activity.

Tolfenamic acid is a selective COX-2 inhibitor, which was marketed in Europe for the treatment of acute migraine disorders. Tolfenamic acid is currently unavailable for human use, however, it may be prescribed for veterinary purposes.